Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Becton, Dickinson and Company (NYSE:BDX) by 34.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 105,188 shares of the medical instruments supplier’s stock after purchasing an additional 27,169 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Becton, Dickinson and were worth $20,612,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Almanack Investment Partners LLC. purchased a new position in Becton, Dickinson and in the 1st quarter worth approximately $105,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in Becton, Dickinson and by 55.8% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 240 shares in the last quarter. Parkside Financial Bank & Trust lifted its stake in Becton, Dickinson and by 8.1% in the 2nd quarter. Parkside Financial Bank & Trust now owns 684 shares of the medical instruments supplier’s stock worth $133,000 after purchasing an additional 51 shares in the last quarter. Harfst & Associates Inc. lifted its stake in Becton, Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock worth $135,000 after purchasing an additional 221 shares in the last quarter. Finally, Financial Architects Inc lifted its stake in Becton, Dickinson and by 8.0% in the 2nd quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after purchasing an additional 54 shares in the last quarter. 87.91% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have weighed in on BDX shares. Wells Fargo & Company reissued a “positive” rating and issued a $235.00 target price (up from $225.00) on shares of Becton, Dickinson and in a research note on Tuesday, October 24th. They noted that the move was a valuation call. BidaskClub lowered shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies reissued a “buy” rating and issued a $213.00 target price on shares of Becton, Dickinson and in a research note on Tuesday, September 12th. Morgan Stanley raised their target price on shares of Becton, Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $230.00 price target (up previously from $210.00) on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Four analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $217.08.

In related news, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the sale, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Stephen Sichak sold 11,787 shares of Becton, Dickinson and stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $200.46, for a total transaction of $2,362,822.02. Following the completion of the sale, the insider now owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company (NYSE:BDX) traded up $5.33 during trading on Wednesday, reaching $226.83. 1,476,500 shares of the company traded hands, compared to its average volume of 1,323,648. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $227.50. The company has a debt-to-equity ratio of 1.48, a current ratio of 5.56 and a quick ratio of 5.01. The firm has a market cap of $50,405.64, a P/E ratio of 23.34, a PEG ratio of 1.73 and a beta of 1.04.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.37 by $0.03. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 22.51%. The firm had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.14 billion. During the same quarter last year, the firm earned $2.12 EPS. The firm’s revenue for the quarter was down 2.0% on a year-over-year basis. research analysts predict that Becton, Dickinson and Company will post 10.63 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be issued a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.32%. The ex-dividend date is Thursday, December 7th. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.73. Becton, Dickinson and’s dividend payout ratio (DPR) is 62.80%.

WARNING: This article was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/22/zurcher-kantonalbank-zurich-cantonalbank-grows-holdings-in-becton-dickinson-and-company-bdx.html.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.